Overview

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects

Status:
RECRUITING
Trial end date:
2026-05-13
Target enrollment:
Participant gender:
Summary
This is a Phase 1, single-center, randomized, placebo-controlled, ascending dose study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), preliminary efficacy, safety and tolerability of BGM0504 following daily oral administrations in non-diabetic overweight or obese adult subjects.
Phase:
PHASE1
Details
Lead Sponsor:
BrightGene Bio-Medical Technology Co., Ltd.